bradanicline Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.   Wikipedia

Chemistry

  • SMILES: O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc3cccnc3)c4oc5ccccc5c4
  • InChIKey: OXKRFEWMSWPKKV-GHTZIAJQSA-N
  • Mol. Mass: 361.45
  • ALogP: 3.26
  • ChEMBL Molecule:
    bradanicline  
More Chemistry

Pharmacology

Alternative names

bradanicline | n-(2-(pyridin-3-ylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-1-benzofuran-2-carboxamide | tc5619 | tc 5619 | tc-5619 | tc-5619-238

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Alzheimer Disease (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Cognitive Dysfunction (Phase 2)

Cough (Phase 2)

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue